LABRHA participated in the last OARSI Congress which took place from the 31st of March to the 3rd of April 2016 in Amsterdam. The company presented the results of the double-blind, controlled, multicenter, randomized trial conducted on 226 patients and comparing the efficacy and tolerance of HAppyVisc® vs. Euflexxa®. Read more…
LABRHA participated in the 3rd International Symposium on Intra-Articular Treatment (ISIAT) Congress which took place in Budapest last 1-3 October 2015. The following 4 oral communications were presented for the company by Dr. Thierry Conrozier: Safety and efficacy of intra articular injections of a combination of hyaluronic acid and mannitol Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. After the success of the 1st Edition last 22-23 May 2014, LABRHA has decided to continue the adventure and launch the 2nd Edition of the European Board on Viscosupplementation. This 2nd Edition Read more…
LABRHA is supporting Eurovisco by organizing its annual board since 2014. We are proud to be Eurovisco’s partner. Consensus statement on viscosupplementation with hyaluronic acid for the management of OA. Y. Henrotin; R. Raman; P. Richette; H. Bard, J. Jerosch; T. Conrozier; X. Chevalier; A. Migliore. Semin Arthritis Rheum. 2015 Read more…
LABRHA actively participated in the 27th Annual Congress of the French Society of Rheumatology which took place in Paris from 7 to 9 December 2014. LABRHA was present with a booth in the exhibition area (F4-F5) where the company’s innovative portfolio and scientific projects were presented to the medical community. Read more…